Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants

Microbes and Infection

Volumn 4, Issue 13, 2002, Pages 1281-1290

  Bozza, Silvia ^a   Gaziano, Roberta ^b   Lipford, Grayson B ^c,d   Montagnoli, Claudia ^a   Bacci, Angela ^a   Di Francesco, Paolo ^b   Kurup, Viswanath P ^e   Wagner, Hermann ^e   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c PFIZER INC   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Fungi; Vaccination

Indexed keywords

ALLERGEN; FUNGUS ANTIGEN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; IMMUNE RESPONSE; INFECTION RESISTANCE; LUNG ASPERGILLOSIS; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; FUNGAL PROTEINS; FUNGAL VACCINES; INFLAMMATION; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; TH1 CELLS;

ASPERGILLUS; FUNGI; MURINAE;

EID: 0036848617     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)00007-2     Document Type: Article

References (60)

1. Denning D.W. Invasive Aspergillosis. Clin. Infect. Dis. 26:1998;781-805.
2. Babbin B.A., Greene J.N., Vega R., Iravani S., Ku Ni Ni, Sandin R.L. Pathologic manifestation of invasive pulmonaryaspergillosis in cancer patients: the many faces of Aspergillus. Cancer Control. 7:2000;566-571.
3. Stevens D.A., Kan V.L., Judson M.A. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:2000;696-709.
4. Latgé J.P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:1999;310-350.
5. Latgé J.P. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9:2001;382-389.
6. Roilides E., Katsifa H., Walsh T.J. Pulmonary host defenses against Aspergillus fumigatus. Res. Immunol. 149:1998;454-465.
7. Schaffner A., Douglas H., Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Invest. 69:1982;617-631.
8. Levitz S., Selsted M.E., Ganz T., Lehrer R.I., Diamond R.D. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J. Infect. Dis. 154:1986;483-489.
9. Cenci E., Mencacci A., Fè d'Ostiani C., et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J. Infect. Dis. 178:1998;1750-1760.
10. Cenci E., Mencacci A., Del Sero G., et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type 1 responses. J. Infect. Dis. 180:1999;1957-1968.
11. Cenci E., Mencacci A., Bacci A., Bistoni F., Kurup V.P., Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J. Immunol. 165:2000;381-388.
12. Cenci E., Mencacci A., Casagrande A., Mosci P., Bistoni F., Romani L. Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J. Infect. Dis. 184:2001;610-617.
13. Wolach B., Alon E., Gottesman G., Yellin A. Pulmonary aspergillosis in a child with hyperimmunoglobulin E syndrome. J. Infect. Dis. 26:1998;204-205.
14. Roilides E., Dimitriadou A., Kadiltsoglou I., Sein T., Karpouzas J., Pizzo P.A., Walsh T.J. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J. Immunol. 158:1997;322-329.
15. Kurup V.P., Hari V., Guo J., Murali P.S., Resnick A., Krishnan M., Fink J.N. Aspergillus fumigatus peptides differentially express Th1 and Th2 cytokines. Peptides. 17:1996;183-190.
16. Crameri R., Hemmann S., Ismail C., Menz G., Blaser K. Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int. Immunol. 10:1998;1211-1216.
17. Banerjee B., Greenberger P.A., Fink J.N., Kurup V.P. Immunological characterization of Asp f 2, a major allergen from Aspergillus fumigatus associated with allergic bronchopulmonary aspergillosis. Infect. Immun. 66:1998;5175-5182.
18. Kurup V.P., Mauze S., Choi S., Seymour B.W., Coffman R.B. A murine model of allergic bronchopulmonary aspergillosis with elevated eosinophils and IgE. J. Immunol. 148:1992;3783-3788.
19. Knutsen A.P., Mueller K.R., Levine A.D., Choulan B., Hutcheson P.S., Slavin R.G. Asp f I CD4+ TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. 94:1994;215-221.
20. Crameri R., Faith A., Hemmann S., Jaussi R., Ismail C., Menz G., Blaser K. Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. J. Exp. M. 184:1996;265-270.
21. 2 protein. J. Exp. M. 189:1999;1507-1512.
22. Grünig G., Corry D.B., Leach M.V., Seymour B.W.P., Kurup V.P., Rennick B.M. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. M. 185:1997;1089-1099.
23. Kurup V.P., Choi H.Y., Murali P.S., Xia J.Q., Coffman R.L., Fink J.N. Immune responses to Aspergillus antigen in IL-4-/- mice and effect of eosinophil ablation. Allergy. 54:1999;420-427.
24. Bozza S., Gaziano R., Spreca A., Bacci A., Montagnoli C., di Francesco P., Romani L. Dendritic Cells Transport Conidia and Hyphae of Aspergillus fumigatus from the Airways to the Draining Lymph Nodes and Initiate Disparate Th Responses to the Fungus. J. Immunol. 168:2002;1362-1371.
25. Grazziutti M., Przepiorka D., Rex J.H., Braunschweig I., Vadhan-Raj S., Savary C.A. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Transplant Marrow. 27:2001;647-652.
26. Medzhitov R., Janeway C. Jr. The Toll receptor family and microbial recognition. Trends Microbio. 8:2000;452-456.
27. Aderem A., Ulevitc R.J. Toll-like receptor family and control of innate immunity. Nature. 406:2000;782-787.
28. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:2001;675-680.
29. Krieg A.M., Yi A., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
30. Wagner H. Bacterial CpG-DNA activates immune cells to signal "infectious danger" Adv. Immunol. 73:1999;329-368.
31. Hemmi H., Tacheuchi O., Takeda K. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
32. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA. 98:2001;9237-9242.
33. Kadowaki N., Antoneko S., Liu Y.J., Distinct Cp G. DNA and polyinosinic-polycitidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2001;2291-2295.
34. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J. Exp. M. 186:1997;1623-1631.
35. Carson D.A., Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. M. 186:1997;1621-1622.
36. Lipford G.B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 165:2000;1228-1235.
37. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:2002;1659-1663.
38. Serebrisky D., Teper A.A., Huang C.K., Lee S.Y., Zhang T.F., Schofield B.H., Kattan M. CpG oligodeoxynucleotides can reverseTh2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 165:2000;5906-5912.
39. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162:1999;6284-6293.
40. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164:2000;5575-5582.
41. Kurup V.P., Xia J.Q., Crameri R., Richaby D.A., Choi H.Y., Fluckiger S., Blaser K., Dawson C.A., Kelly K.J. Purified recombinant A. fumigatus allergens induce different responses in mice. Clin. Immunol. 98:2001;327-336.
42. Crameri R., Blaser K. Allergy and immunity to fungal infections and colonization. Eur. Respir. J. 19:2002;151-157.
43. Lipford G.B., Sparwasser T., Bauer M., Zimmermann S., Koch E.S., Heeg K., Wagner H. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:1997;3420-3426.
44. Hemmann S., Blaser K., Crameri R. Recombinant allergens from Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes. Am. J. Resp. Crit. Care M. 156:1997;1956-1962.
45. Kumar A., Reddy L.V., Sochanik A., Kurup V.P. Isolation and characterization of a recombinant heat shock protein of A. fumigatus. J. Allergy Clin. Immunol. 91:1993;1024-1030.
46. Banerjee B., Kurup V.P., Greenberger P.A., Johnson B.D., Fink J.N. Cloning and expression of Aspergillus fumigatus allergen Aspf 16 mediating both humoral and cell mediated immunity in allergic bronchopulmonary aspergillosis ABPA. Clin. Exp. Allergy. 31:2001;761-770.
47. Fè d'Ostiani C., Del Sero G., Bacci A., et al. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans: implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. M. 191:2000;1661-1673.
48. Bacci A., Montagnoli C., Perruccio K., Bozza S., Gaziano R., Velardi A., Fe' d'Ostiani C., Romani L. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J. Immunol. 168:2002;2904-2913.
49. Holt P.G. Antigen presentation in the lung. Am. J. Respir. Crit. Care M. 2000;S151-S162.
50. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immun. 2:2001;725-731.
51. Vermaelen K.Y., Carro-Muino I., Lambrecht B.N., Pauwels R.A. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. M. 193:2001;51-60.
52. Sieling P.A., Modlin R.L. Toll-like receptors: mammalian "taste receptors" for a smorgasbord of microbial invaders. Curr. Opin. Microbiol. 5:2002;70-75.
53. Cenci E., Mencacci A., Spreca A., et al. Killer antidiotypes protect from invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect. Immun. 70:2002;2375-2382.
54. Appenzeller U., Mayer C., Menz G., Blaser K., Crameri R. IgE-mediated reaction to autoantigens in allergic diseases. Int. Arch. Allergy Immunol. 118:1999;193-196.
55. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunization using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 19:2000;413-422.
56. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine. 18:1999;231-237.
57. Weighardt H., Feterowski C., Veit M., Rump M., Wagner H., Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 165:2000;4537-4543.
58. Schwartz D.A., Wohlford-Lenane C.L., Quinn T.J., Krieg A.M. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolisaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J. Immunol. 163:1999;224-231.
59. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., Trezza R.P., Heinzel F.P., Forsthuber T., Lehmann P.V. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:1999;3942-3949.
60. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nature Biotechnol. 17:1999;1075-1081.